Botulinum neurotoxin in muscle overactivity.
Esquenazi
Alberto
A
Department of Physical Medicine and Rehabilitation, MossRehab and Albert Einstein Medical Center, Elkins Park, PA 19027, USA.
D001905:Botulinum Toxins / Q000009:adverse effects / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009128:Muscle Spasticity / Q000175:diagnosis* / Q000188:drug therapy*; D018482:Muscle, Skeletal / Q000187:drug effects; D009498:Neurotoxins / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016896:Treatment Outcome
D009498:Neurotoxins; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A